Qiagen N.V.

Equities

QGEN

NL0015002SN0

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:01:48 2026-03-13 pm EDT			5-day change	1st Jan Change
40.60 ^USD	-1.26%		-8.87%	-14.23%

Mar. 13	Frankfurt Market Close: Dax continues to slide - Risk aversion persists amid oil concerns	DP
Mar. 13	Wall Street Clings to Hope

Qiagen N : DWS Investment GmbH - Qiagen N.V. - VENLO

Published on 02/04/2026 at 05:51 pm EST

Publicnow

QIAGEN N.V.

-1.26%

DWS Investment GmbH - Qiagen N.V. - VENLO

DWS Investment GmbH - Qiagen N.V. - VENLO

Below you will find information from the register substantial holdings and gross short positions. The information has been provided by the organisation.

Date of transaction03 feb 2026

Person obliged to notifyDWS Investment GmbH

Issuing institutionQiagen N.V.

Registration Chamber of Commerce12036979

Place of residenceVENLO

Previous result

Next result

Date last update: 04 February 2026

Attachments

Original document
Permalink

Disclaimer

Qiagen NV published this content on February 03, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on February 04, 2026 at 22:50 UTC.

Latest news about Qiagen N.V.

Mar. 13	Frankfurt Market Close: Dax continues to slide - Risk aversion persists amid oil concerns	DP
Mar. 13	Wall Street Clings to Hope
Mar. 13	Deutsche Bank Upgrades Qiagen to Buy Rating, Lifts PT	MT
Mar. 13	Analyst recommendations: Adobe, Oracle, Dow, Him & Hers, Whirlpool…
Mar. 13	QIAGEN NV : Upgraded to Buy by Deutsche Bank	ZD
Mar. 11	Qiagen receives U.S. clearance for gastrointestinal panels on fully automated Qiastat-Dx Rise syndromic testing system	RE
Mar. 10	QIAGEN Gets US FDA Clearance for Gastrointestinal Panels on Automated Syndromic Platform	MT
Mar. 10	Qiagen N.V. Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated Qiastat-Dx Rise Syndromic Testing System	CI
Mar. 10	Qiagen N.V. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 08:30 AM
Mar. 09	Qiagen N.V. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 11:20 AM
Mar. 02	Qiagen N.V. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:10 AM
Feb. 24	DiaSorin Unveils New LIAISON QuantiFERON-TB Gold Plus II Test	AN
Feb. 20	QIAGEN NV : Barclays gives a Buy rating	ZD
Feb. 19	QIAGEN NV : Jefferies reiterates its Buy rating	ZD
Feb. 17	U.S. Futures Down, European Stocks Up	DJ

Chart Qiagen N.V.

Duration

Period

QGEN: Dynamic Chart

Company Profile

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Employees

5,654

Sector

Biotechnology & Medical Research

More about the company